Objective: To validate the Synkinesis Assessment Questionnaire (SAQ), a newly developed patientgraded instrument to evaluate facial synkinesis. Study Design: This was a prospective clinical questionnaire validation study. Methods: A total of 65 patients with facial nerve disorders were recruited from the Facial Nerve Center. In 28 patients (group I), the SAQ, a preliminary 10-item instrument, was administered at the initial visit and repeated within 3 weeks without any medical or surgical intervention. In 37 patients (group II), the SAQ was administered before botulinum toxin therapy for facial synkinesis and again 2 weeks after Botox therapy. In addition, the instrument was administered to 20 healthy subjects without facial nerve dysfunction (group III). The reliability, validity, and responsiveness of the SAQ were assessed. Results: Test-retest reliability for the SAQ was high (Spearman's rank correlation r ‫؍‬ 0.876, P < .0001). Internal consistency of the instrument was assessed by calculating the Cronbach ␣ value. This analysis supported the deletion of one item from the final SAQ. The Cronbach ␣ for the final SAQ was 0.859. Construct validity analysis showed a statistically significant improvement in SAQ scores (P < .001) after successful administration of botulinum toxin for treatment of facial synkinesis. There was a highly statistically significant difference (P < .0001) in SAQ scores between normal subjects (group III) and patients with facial synkinesis (group II). Conclusions: The SAQ is a simple, patient-graded instrument designed to assess facial synkinesis. Instrument analysis suggests that it is a reliable and valid instrument for the assessment of facial synkinesis. The validated SAQ is the first dedicated instrument designed to assess facial synkinesis.
INTRODUCTION
Facial synkinesis is one of the most distressing consequences of facial paralysis. Synkinesis refers to the abnormal involuntary facial movement that occurs with voluntary movement of a different facial muscle group. The pathophysiologic basis of facial synkinesis is abnormal regeneration of facial nerve fibers to the facial muscle groups. Because of this abnormal regeneration, patients experience hypertonic contractures and synkinetic movements such as eye closure with volitional movement of the mouth or midfacial movement during volitional or reflexive eye closure. Patients frequently complain of synkinesis in the platysma, which can lead to neck tightness. Synkinesis can lead to functional limitations with activities such as eating, drinking, smiling, and may even lead to social isolation.
The most common therapeutic modalities for the treatment of facial synkinesis include 1) botulinum toxin type A injections for selective chemodenervation of affected muscle groups and 2) facial neuromuscular retraining. 1,2 Biofeedback using mirrors or electromyography has been used both for the treatment and prevention of facial synkinesis. Other treatment options include surgical therapies, such as selective neurolysis or myectomy. 3 Despite the significant impact that facial synkinesis has on the quality of life of patients with facial paralysis, there is no universally accepted method of grading facial synkinesis. In fact, a specific instrument to assess synkinesis does not exist. Grading of synkinesis as a part of the Sydney and Sunnybrook Facial Grading Systems (FGS) was found to have low reliability both within and between systems. 4 The most commonly used facial nerve grading system, the House-Brackmann system, also does not reliably assess synkinesis and is inadequate in patients with partial facial function. 4, 5 Several authors have attempted to quantify synkinesis using an objective computerized system. However, these systems have not gained widespread acceptance because they are cumbersome and require significant processing time. 6, 7 Recently, a new instrument to measure impairment and disability in patients with facial paralysis was developed and validated. The Facial Clinimetric Evaluation (FaCE) scale is composed of 15 items evaluating 6 domains of facial impairment and disability. Although the instrument was found to be reliable and valid, it does not adequately assess synkinesis. 8 The goal of the present study is to validate a newly developed patient-graded instrument designed specifically to evaluate facial synkinesis. The Synkinesis Assessment Questionnaire (SAQ) is a nine-item questionnaire that focuses on the assessment of facial synkinesis.
METHODS
The SAQ items were developed by the senior author in response to the most frequent complaints associated with facial synkinesis seen at the Facial Nerve Center at the Massachusetts Eye and Ear Infirmary, Boston, MA. A total of 10 items were included on the original SAQ (Fig. 1) . Each item is scored on a scale from 1 to 5. The overall score is converted to a 0 to 100 scale, whereby higher scores represent more synkinesis.
A prospective, clinical study was designed to validate the instrument. The study was approved by the Institutional Review Board at the Massachusetts Eye and Ear Infirmary. A total of 65 patients with facial nerve paralysis were recruited from the Facial Nerve Center at the Massachusetts Eye and Ear Infirmary. In addition to informed consent forms, each subject filled out the following: FaCE questionnaire and the SAQ. When possible, each subject's facial function was also graded using the HouseBrackmann grading system and the Sunnybrook FGS. Inclusion criteria included an age greater than 12 years and a history of facial nerve palsy. Twenty controls were also recruited. Controls were required to have no history of facial palsy, no history of botulinum toxin injections to the face or neck, and no history of stroke or major surgery to the head and neck region. Control subjects were only required to fill out the SAQ. All data were entered into a Microsoft Excel (Microsoft, Redmond, WA) database, and analysis was performed using Statview 5.0 (SAS Institute, Cary, NC).
Reliability and Validity Analysis
Test-retest reliability was assessed in a group of 28 patients (group I) in whom the SAQ was administered at the initial visit and repeated within 3 weeks. There was no medical or surgical intervention during the 3 week interval. Internal consistency of the instrument was assessed by calculating Cronbach ␣ coefficient for the SAQ. In 37 patients (group II), the SAQ was administered before botulinum toxin therapy and again 2 weeks after botulinum toxin therapy. Group II was used to assess the responsiveness of the instrument to clinical intervention. The instrument was also administered to 20 normal controls (group III). A subset of 39 patients were graded using the FGS. A correlation analysis between SAQ scores and the synkinesis portion of the FGS scores was performed.
RESULTS
A total of 65 patients (48 female, 17 male) with a mean age of 46.8 Ϯ 14.2 years completed the questionnaires. The diagnoses for these patients are listed in Table I . Twenty normal subjects were also recruited (12 female, 8 male) with a mean age of 38.5 Ϯ 15.2 years and completed the SAQ.
Test-Retest Reliability and Internal Consistency
Internal consistency analysis supported the reduction of one item from the SAQ. Item 9 showed poor interim correlation and test-retest reliability. In addition, several patients reported that item 9 was difficult to comprehend. Item 9 was thus deleted, making the final SAQ a nineitem questionnaire. Test-retest reliability for the SAQ was high (Spearman's rank correlation r ϭ 0.881, P Ͻ .0001). The individual item and total correlation coefficients are shown in Table II . Internal consistency of the instrument was assessed with Cronbach ␣ value that was calculated to be 0.863 (␣ Ͼ 0.60 considered robust). 
Construct Validity and Responsiveness
For patients in group II (n ϭ 37), the mean score before botulinum toxin therapy was 43.6 Ϯ 15.6 (1 SD). The mean SAQ score 2 weeks after botulinum toxin therapy improved to 25.7 Ϯ 17.2 (Fig. 2) . This difference was highly statistically significant using Student's t test (P Ͻ .00001). Patients in group II were also compared with normal subjects (group III) (Fig. 3) . The mean SAQ score in group III was 1.67 Ϯ 3.52. The difference between SAQ scores of prebotulinum toxin group II patients and normal subjects (group III) was highly statistically significant (P Ͻ .0001). Responsiveness of the SAQ to synkinesis treatment with botulinum toxin was further assessed by evaluating SAQ scores in a subset of eight patients who had been treated with botulinum toxin for two cycles. In this subset, mean SAQ scores worsened from 15.6 Ϯ 8.5 postbotulinum toxin therapy to 31.8 Ϯ 15.6 prebotulinum toxin for the next cycle, consistent with clinical deterioration in synkinesis as the effects of botulinum toxin wear off (Fig. 4) .
To assess convergent validity, the SAQ scores were correlated with the FGS synkinesis scores in a group of 39 patients. A statistically significant correlation of 0.769 was measured (P Ͻ .0001).
DISCUSSION
The specific assessment of synkinesis is critical to the evaluation of patients with facial paralysis. Hypertonic contractures and synkinesis represent the most common sequelae of aberrant facial nerve regeneration after insult to the facial nerve. In recent years, botulinum toxin therapy and facial neuromuscular training have emerged as the Fig. 2 . Mean Synkinesis Assessment Questionnaire scores before and after botulinum toxin therapy (n ϭ 37; P Ͻ .00001). mainstay of therapy for this condition. Despite the obvious clinical benefit that patients receive from treatment of synkinesis, there is no dedicated instrument that attempts to quantify and monitor synkinesis. With the effects of botulinum toxin lasting an average of 3 to 4 months, the treatment of synkinesis is cyclical, with worsening of the signs and symptoms of synkinesis as it wears off between treatments. A dedicated instrument to the evaluation of facial synkinesis is thus a valuable adjunct evaluating and treating patients with facial nerve disorders.
In this study, we demonstrate the reliability, validity, and responsiveness of the SAQ, a new nine-item questionnaire dedicated to the evaluation of facial synkinesis. The SAQ was found to have high test-retest reliability and robust internal consistency (Cronbach ␣ 0.863). A Cronbach ␣ of 0.7 or greater is widely accepted as a reliable measure. 9 The SAQ responsiveness to botulinum toxin treatment of synkinesis (Figs. 2 and 4) supports construct validity. The SAQ was compared with the synkinesis subset of scores on a previously validated facial nerve disorders questionnaire, the FGS. A statistically significant positive correlation of 0.769 supports convergent validity of the SAQ. Normal subjects with no facial synkinesis had extremely low SAQ scores, as predicted (Fig. 3) .
The SAQ is a simple, easy to administer, patientgraded instrument that reliably assesses facial synkinesis. It can easily be administered in a busy clinical setting at minimal cost and offers an excellent mechanism to track the cyclical nature of synkinesis symptoms with relation to botulinum toxin therapy. The SAQ, however, is a subjective assessment of synkinesis. It is designed to be used in conjunction with clinical patient examination as a determinant of treatment results. The next major advance in the assessment of facial synkinesis will likely be automated computerized objective measurements of synkinesis. To date, however, objective measurements of synkinesis are cumbersome, require markers on the face, and involve significant processing time, making them unrealistic for rapid assessment of synkinesis in the clinical setting. 6, 7, 10 
CONCLUSION
The SAQ is a simple, patient-graded instrument designed to assess facial synkinesis. Instrument analysis suggests that it is a reliable and valid instrument for self-assessment of facial synkinesis. The validated SAQ is the first dedicated instrument designed to assess facial synkinesis. 
